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COMMENT & RESPONSE
Presurgery Sedation and Patient Experience
To the Editor In a randomized clinical trial by Dr Maurice-
Szamburski and colleagues,1 premedication with oral loraze-
pam 2 hours prior to arriving in the operating room did not im-
prove patient satisfaction after surgery and was associated with
prolonged time to extubation and decreased cognitive recov-
ery compared with placebo or no medication. These results may
not indicate that all sedative premedication is unwarranted but
may suggest lorazepam is inadequate.
Maurice-Szamburski and colleagues explained why loraze-
pam was used instead of midazolam for their trial: “The choice
of lorazepam was motivated by its use in the largest survey of
sedative premedication published to date,” referring to a study
by Kain et al.2 There is some discrepancy between this statement
and the survey results, in which among adults, the most com-
monly used sedative premedication was midazolam (>75%), fol-
lowed by diazepam (7%), and lorazepam (2%).2 Seven years later,
a follow-up survey study by Kain et al3 found that adult inpatients
received midazolam most often (80%), followed by diazepam
(3%), fentanyl (2%), and lorazepam (1%).
Lorazepam may have disadvantages compared with mid-
azolam. Midazolam is a short-acting benzodiazepine with an
elimination half-life of 2.0 hours to 2.5 hours, whereas lora-
zepam has a half-life of 10 hours to 20 hours. In a randomized
clinical trial that compared midazolam with lorazepam for post-
operative sedation, delays in emergence from sedation were
observed in the lorazepam group.4
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To the Editor The key purpose of patient premedication with
benzodiazepines is preoperative anxiolysis,1 which allows for
safer monitoring and induction of anesthesia. In contrast, the
primary outcome parameter of the study by Dr Maurice-
Szamburski and colleagues2 was the patient’s perception quan-
tified with a patient satisfaction index (Evaluation du Vécu de
l’Anesthésie Generale; EVAN-G)3 on the first postoperative day.
From a clinical viewpoint, a patient’s perception on the first
postoperative day is not the key parameter to judge the value
of premedication.
Themoreimportantoutcomeswerethesecondaryoutcomes
measuring preoperative and intraoperative conditions. Anxiety
upon arrival in the operating room was significantly lower (visual
analog scale scores for anxiety: 35 points for lorazepam group vs
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44 points for placebo group; P = .001). However, the scores for
quality of conditioning and well-being upon arrival in the oper-
ating room were not statistically significant. The present study
wasunderpoweredtoshedlightontheseclinicallyimportantand
desired effects of premedication.
In the lorazepam group, the duration of surgery was 11 min-
utes longer than in the placebo group and postoperative pain
was significantly lower. The statistically significant second-
ary outcome of a prolonged time to extubation can be attrib-
uted to lorazepam only if dosages of sedatives and opioids were
comparable between the groups, which were not presented in
the article.
Because many patients do not want to remember anything
about the operation, amnesia is an intended effect of premedi-
cation. The increased proportion of patients with amnesia (24%
with lorazepam vs 6% with placebo) is a beneficial effect of lor-
azepam rather than a complication as the authors suggested.
Lorazepam produced clinically desired effects in the study
by Maurice-Szamburski and colleagues. The data do not jus-
tify the conclusion of the authors that lorazepam lacks any ben-
efit in routine use.
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In Reply If midazolam remains the most prescribed sedative pre-
medication, lorazepam ranks third for outpatient surgery and
fourth for inpatient surgery.1 Midazolam and lorazepam both
belong to the benzodiazepine class and share most of their in-
dications. The PremedX study evaluated sedative premedica-
tion with lorazepam given orally 2 hours before surgery. Lor-
azepam was chosen over the more commonly used midazolam
because, due to its shorter acting time, midazolam may not
have been as potent as lorazepam upon arrival in the operat-
ing room.
In the study by Barr et al cited by Dr Fujita, these 2 drugs
were the most frequently prescribed drugs for sedation. How-
ever, one should be careful about extrapolating results from
this intensive care unit study with continuous administra-
tion of benzodiazepine and fentanyl up to 72 hours. Although
delays in emergence were longer in the lorazepam group, the
lengths of administration differed (mean [SD], 36.94 [30.90]
hours with midazolam vs 15.02 [3.33] hours with lorazepam).2
In response to Drs Heller and Koch, we believe the purpose
of premedication is not established. According to anesthetists,
there are many different reasons for using sedative
premedication.3 Because sedative premedication primarily con-
cernspatientsandtheirexperience,4 themainoutcomeofthePre-
medX study was the patient experience and satisfaction assessed
by a validated questionnaire, evaluating both the preoperative,
perioperative, and postoperative periods.5 The EVAN-G mean
global index showed no significant differences between the lor-
azepam, placebo, and no premedication groups in the whole
population or in the subgroup of the most anxious patients, those
expected to benefit the most from sedative premedication.
Even though anxiety upon operating room arrival was
lower with lorazepam than with placebo, it was no different
between lorazepam and no premedication (35 [95% CI, 32-38]
vs 38 [95% CI, 35-41], respectively, P = .41) and was higher com-
paring placebo with no premedication (44 [95% CI, 40-47] vs
38 [95% CI, 35-41], respectively, P = .05), suggesting a nocebo
effect of placebo. In our study, anesthetists were unable to dis-
tinguish between the lorazepam, placebo, and no premedica-
tion groups for quality of patient conditioning. Before invok-
ing underpowering to explain the lack of efficacy, sedative
premedication relevance should be questioned.
The randomization of the study was intended to elimi-
nate other sources of variability, such as the dosing of seda-
tives and opioids. The types of drugs used for the anesthesia
protocol were not different between groups.
Lorazepam was associated with a 10-point lower satisfac-
tion score on the attention dimension of the EVAN-G scale. One
explanation is that the amnesia from benzodiazepine led pa-
tients to forget the attention they received from caregivers,
which would not necessarily be beneficial.
Given the results of the PremedX study, we continue to be-
lieve that routine sedative premedication with benzodiaz-
epine should not be recommended.
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